Previous close | 14.12 |
Open | 14.14 |
Bid | 14.25 x 1800 |
Ask | 14.26 x 2900 |
Day's range | 14.15 - 14.27 |
52-week range | 13.05 - 17.31 |
Volume | |
Avg. volume | 2,616,216 |
Market cap | 44.252B |
Beta (5Y monthly) | 0.80 |
PE ratio (TTM) | 30.32 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.80 (5.65%) |
Ex-dividend date | 29 Sept 2021 |
1y target est | N/A |
OSAKA, Japan, July 28, 2022--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the first quarter of fiscal year 2022 (period ended June 30, 2022) and is on track to meet its full-year management guidance.
OSAKA, Japan & CAMBRIDGE, Mass., July 21, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase 3 clinical trial evaluating HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint. Topline data show that HYQVIA reduced relapse of neuromuscular disability and impairment when used as a
OSAKA, Japan, July 11, 2022--Takeda Pharmaceutical Company Limited ("Takeda") (TOKYO:4502/NYSE:TAK) today announced that it has filed its Corporate Governance Report with the Tokyo Stock Exchange ("TSE") in accordance with the regulations* for TSE listed companies. The Report can be accessed on Takeda’s website at: https://www.takeda.com/who-we-are/corporate-governance/.